Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG7774 · 1 trial · 1 indication
The ETDRS DRSS is a standardized grading test to measure diabetic retinopathy progression, where higher scores indicate a higher risk of vision loss. The DRSS ranges from level 10 (no diabetic retinopathy) to level 85 (advanced diabetic retinopathy)
| Arm | Type | Description |
|---|---|---|
| Group A | PLACEBO_COMPARATOR | Participants will receive an oral dose of placebo matched to RG7774 once daily (QD) |
| Group B | EXPERIMENTAL | Participants will receive a low oral dose of RG7774 QD |
| Group C | EXPERIMENTAL | Participants will receive a high oral dose of RG7774 QD |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Participants will receive oral placebo matched to RG7774 |
| RG7774 | DRUG | Participants will receive oral RG7774 |
Inclusion Criteria * Able and willing to provide written informed consent and to comply with the study protocol according to International Conference of Harmonization (ICH) and local regulations * Male and female patients of at least 18 years of age * Treatment naïve with moderately severe to sever...
RG7774 is an investigational small molecule being developed for diabetic retinopathy, a complication of diabetes that affects the eyes. It is being studied in patients with diabetes mellitus type 1 or type 2 who have treatment-naive diabetic retinopathy. The drug is currently in Phase 2 clinical development.
RG7774 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY. The company is conducting clinical trials to evaluate the safety and efficacy of RG7774 in patients with diabetic retinopathy.
RG7774 is in Phase 2 clinical development. A Phase 2 study of RG7774 has been completed, which evaluated the drug's efficacy and safety in patients with diabetes mellitus type 1 or type 2 with treatment-naive diabetic retinopathy. The drug is not yet approved and remains investigational.
RG7774 has one completed Phase 2 clinical trial registered under NCT04265261. The study investigated the efficacy and safety of RG7774 in patients with diabetes mellitus type 1 or type 2 with treatment-naive diabetic retinopathy. The trial enrolled 139 participants across the United States, Australia, Poland, Puerto Rico, Slovakia, Spain, and the United Kingdom.
RG7774 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for diabetic retinopathy. A Phase 2 clinical trial has been completed, but the drug has not yet received regulatory approval for any use.